Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 29137.50
NRIFF's Cash to Debt is ranked higher than
100% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. NRIFF: 29137.50 )
NRIFF' s 10-Year Cash to Debt Range
Min: 0.19   Max: 29137.5
Current: 29137.5

0.19
29137.5
Equity to Asset 0.86
NRIFF's Equity to Asset is ranked higher than
92% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. NRIFF: 0.86 )
NRIFF' s 10-Year Equity to Asset Range
Min: -0.05   Max: 0.98
Current: 0.86

-0.05
0.98
F-Score: 5
Z-Score: 1.98
M-Score: -4.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -107.40
NRIFF's Operating margin (%) is ranked higher than
51% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. NRIFF: -107.40 )
NRIFF' s 10-Year Operating margin (%) Range
Min: -1350.37   Max: 42.55
Current: -107.4

-1350.37
42.55
Net-margin (%) 295.55
NRIFF's Net-margin (%) is ranked higher than
99% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. NRIFF: 295.55 )
NRIFF' s 10-Year Net-margin (%) Range
Min: -1222.18   Max: 295.55
Current: 295.55

-1222.18
295.55
ROE (%) 127.79
NRIFF's ROE (%) is ranked higher than
100% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. NRIFF: 127.79 )
NRIFF' s 10-Year ROE (%) Range
Min: -978.57   Max: 113.73
Current: 127.79

-978.57
113.73
ROA (%) 96.34
NRIFF's ROA (%) is ranked higher than
100% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. NRIFF: 96.34 )
NRIFF' s 10-Year ROA (%) Range
Min: -153.07   Max: 88.96
Current: 96.34

-153.07
88.96
ROC (Joel Greenblatt) (%) -118.81
NRIFF's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. NRIFF: -118.81 )
NRIFF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1090.44   Max: 859.99
Current: -118.81

-1090.44
859.99
Revenue Growth (3Y)(%) -17.00
NRIFF's Revenue Growth (3Y)(%) is ranked higher than
52% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. NRIFF: -17.00 )
NRIFF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37.7   Max: 48.7
Current: -17

-37.7
48.7
» NRIFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NRIFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1.00
NRIFF's P/E(ttm) is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. NRIFF: 1.00 )
NRIFF' s 10-Year P/E(ttm) Range
Min: 0.88   Max: 207.85
Current: 1

0.88
207.85
PE(NRI) 1.10
NRIFF's PE(NRI) is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. NRIFF: 1.10 )
NRIFF' s 10-Year PE(NRI) Range
Min: 0.88   Max: 19.64
Current: 1.1

0.88
19.64
P/B 0.80
NRIFF's P/B is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. NRIFF: 0.80 )
NRIFF' s 10-Year P/B Range
Min: 0.61   Max: 44.43
Current: 0.8

0.61
44.43
P/S 3.30
NRIFF's P/S is ranked higher than
68% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. NRIFF: 3.30 )
NRIFF' s 10-Year P/S Range
Min: 0.77   Max: 32.5
Current: 3.3

0.77
32.5
PFCF 29.60
NRIFF's PFCF is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. NRIFF: 29.60 )
NRIFF' s 10-Year PFCF Range
Min: 7.46   Max: 57.64
Current: 29.6

7.46
57.64
POCF 23.28
NRIFF's POCF is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. NRIFF: 23.28 )
NRIFF' s 10-Year POCF Range
Min: 7.22   Max: 395.4
Current: 23.28

7.22
395.4
EV-to-EBIT 0.86
NRIFF's EV-to-EBIT is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. NRIFF: 0.86 )
NRIFF' s 10-Year EV-to-EBIT Range
Min: -12.3   Max: 8.3
Current: 0.86

-12.3
8.3
Current Ratio 6.89
NRIFF's Current Ratio is ranked higher than
90% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. NRIFF: 6.89 )
NRIFF' s 10-Year Current Ratio Range
Min: 0.3   Max: 24.2
Current: 6.89

0.3
24.2
Quick Ratio 6.68
NRIFF's Quick Ratio is ranked higher than
91% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. NRIFF: 6.68 )
NRIFF' s 10-Year Quick Ratio Range
Min: 0.19   Max: 23.8
Current: 6.68

0.19
23.8
Days Inventory 93.65
NRIFF's Days Inventory is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. NRIFF: 93.65 )
NRIFF' s 10-Year Days Inventory Range
Min: 75.26   Max: 960.13
Current: 93.65

75.26
960.13
Days Sales Outstanding 84.00
NRIFF's Days Sales Outstanding is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. NRIFF: 84.00 )
NRIFF' s 10-Year Days Sales Outstanding Range
Min: 19.7   Max: 419.77
Current: 84

19.7
419.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.90
NRIFF's Price/Net Cash is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NRIFF: 0.90 )
NRIFF' s 10-Year Price/Net Cash Range
Min: 2.72   Max: 55.19
Current: 0.9

2.72
55.19
Price/Net Current Asset Value 0.80
NRIFF's Price/Net Current Asset Value is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. NRIFF: 0.80 )
NRIFF' s 10-Year Price/Net Current Asset Value Range
Min: 2.1   Max: 4029.9
Current: 0.8

2.1
4029.9
Price/Tangible Book 0.80
NRIFF's Price/Tangible Book is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. NRIFF: 0.80 )
NRIFF' s 10-Year Price/Tangible Book Range
Min: 0.85   Max: 1917.5
Current: 0.8

0.85
1917.5
Price/DCF (Projected) 2.10
NRIFF's Price/DCF (Projected) is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. NRIFF: 2.10 )
NRIFF' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 2.1

Price/Median PS Value 1.00
NRIFF's Price/Median PS Value is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. NRIFF: 1.00 )
NRIFF' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 122.14
Current: 1

0.32
122.14
Price/Graham Number 0.20
NRIFF's Price/Graham Number is ranked higher than
100% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. NRIFF: 0.20 )
NRIFF' s 10-Year Price/Graham Number Range
Min: 1.1   Max: 1.1
Current: 0.2

Earnings Yield (Greenblatt) 117.20
NRIFF's Earnings Yield (Greenblatt) is ranked higher than
99% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NRIFF: 117.20 )
NRIFF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 12.1   Max: 206
Current: 117.2

12.1
206

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:NRI.Canada, DLAN.Germany,
Nuvo Research, Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario. The Company is a publicly traded Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group. The TPT Group has four commercialized products, a pipeline of products at various stages of development focusing on the following therapeutic areas: pain, dermatology, central nervous system (CNS) and endocrinology and four topical and transdermal drug delivery (TTDD) platforms. The Immunology Group has two commercialized products, a development program for the treatment of allergic rhinitis and a potential immune system modulation platform. The Company has four commercialized products: Pennsaid, Pennsaid 2%, the heated lidocaine/tetracaine patch (HLT Patch, formerly known as Synera) and Pliaglis. The Company is building a portfolio of products for the treatment of pain through internal research and development (R&D) and by in-licensing and acquisition. The Company is also involved in R&D activities with WF10, a chlorite-based immune modulating drug, through Nuvo Research AG.
» More Articles for NRIFF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nuvo Research® Provides Business Update Mar 09 2015
Nuvo Research® Provides Business Update Mar 05 2015
NRI.TO: Cash Balance and Pending Phase 3 Trial with Pennsaid 2% Keep Nuvo Research Looking... Feb 20 2015
Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results Feb 19 2015
NRI.TO: WF10 Fails Phase 2 Allergic Rhinitis Study Jan 30 2015
Nuvo Research® Granted Additional U.S. Patent for Treatment of Allergic Rhinitis with WF10™ Dec 22 2014
Nuvo Research reports that all patients have completed Phase 2 study of WF10 for the treatment of... Dec 18 2014
Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and... Nov 13 2014
Nuvo Research® Announces 2014 Third Quarter Results Nov 10 2014
Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals Nov 03 2014
NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon Oct 20 2014
Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma Oct 17 2014
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals Sep 08 2014
Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference Sep 04 2014
(T.NRI) (NRIFF): Nuvo Q2 Results In-Line, Looking Forward to WF10 Data Early 2015 Aug 01 2014
Nuvo Research® announces 2014 second quarter results Jul 30 2014
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference Jun 17 2014
Nuvo Research announces director election results of its annual general meeting Jun 11 2014
Investment In Nuvo Research Looks Like An Easy Call Jun 06 2014
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5% May 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK